Chautauqua Capital Management, a division of Baird Asset Management, is a boutique investment firm that released its second quarter 2025 investor letter for the “Baird Chautauqua International and Global Growth Fund”. A copy of the letter can be downloaded here. Global equity markets experienced a significant shift during the quarter, moving from notable losses to reaching new highs. Markets fell following the President’s announcement of unexpectedly severe tariffs, which raised recession fears. After a brief pause on tariffs, markets regained confidence, closing the quarter at or near all-time highs. In this environment, the Baird Chautauqua International Growth Fund underperformed its benchmark during the quarter. In addition, please check the fund’s top five holdings to know its best picks in 2025.
In its second-quarter 2025 investor letter, Baird Chautauqua International and Global Growth Fund highlighted stocks such as Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases. The one-month return of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was -2.89%, and its shares lost 46.36% of their value over the last 52 weeks. On September 26, 2025, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stock closed at $563.90 per share, with a market capitalization of $59.766 billion.
Baird Chautauqua International and Global Growth Fund stated the following regarding Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in its second quarter 2025 investor letter:
“Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) reported mixed top-line results from a pipeline drug, itepekimab, in Chronic Obstructive Pulmonary Disease (COPD), with one of the two trials meeting expectations. While itepekimab is not expected to be a core driver of Regeneron’s shares, other drug candidates in its pipeline continue to advance.”
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is not on our list of 30 Most Popular Stocks Among Hedge Funds. According to our database, 73 hedge fund portfolios held Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) at the end of the second quarter, up from 66 in the previous quarter. In the second quarter of 2025, Regeneron Pharmaceuticals, Inc.’s (NASDAQ:REGN) total revenues reached $3.7 billion, which represents a 4% growth compared to the previous year. While we acknowledge the potential of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
